<DOC>
	<DOC>NCT00853047</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability of LX1606 versus a placebo control in subjects with symptomatic carcinoid syndrome not managed by stable-dose long-acting octreotide therapy. Following determination of the maximally tolerated or effective dose, cohort expansion will occur to confirm effect on symptoms and safety profile.</brief_summary>
	<brief_title>Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Serotonin Syndrome</mesh_term>
	<criteria>Males and females, aged 18 and older Biopsyproven metastatic carcinoid tumor of the GI tract with disease extent confirmed by CT, MRI, or radionuclide imaging Symptoms not managed by stabledose longacting octreotide therapy (≥4 bowel movements per day) Ability to provide written informed consent ≥12 high volume, watery bowel movements per day Sponsorunacceptable clinical laboratory values for hematology and liver function tests at screening Karnofsky status ≤70% unable to care for self Surgery within 60 days prior to screening A history of short bowel syndrome Life expectancy &lt;12 months History of substance or alcohol abuse within 2 years prior to screening Previous exposure to a tryptophan hydroxylase (TPH) inhibitor Administration of any investigational drug within 30 days of screening or any therapeutic protein or antibody within 90 days of screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>